PRESS-NEWS.org - Press Release Distribution
PRESS RELEASES DISTRIBUTION

New Co-STAR receptor shows promise treating cancers in laboratory study

New Co-STAR receptor shows promise treating cancers in laboratory study
2024-07-10
(Press-News.org) Using genetic engineering techniques, investigators at the Johns Hopkins Kimmel Cancer Center and its Ludwig Center, the Lustgarten Laboratory and Bloomberg~Kimmel Institute for Cancer Immunotherapy have designed a novel type of cell to recognize and fight cancer.

To produce the cells, called Co-STAR (Co-stimulatory Synthetic T-cell receptor and Antigen Receptor) cells, the researchers combined genetic components of four types of cells that the body normally uses to defend against invaders to make a powerful new cell type: T-cell receptors (TCRs) from T cells, antibodies from B cells, MyD88 from white blood cells called monocytes, and CD40 from dendritic and other cells. The TCR and antibody components served as an “invader detecting device,” recognizing cancer cells as foreign, and the “alarm” triggered by this hybrid detector was boosted by the MyD88 and C40 components.   

In laboratory studies, Co-STARs led to a sustained anti-tumor response against human cancer cells growing in test tubes and in mice. A description of the work was published July 10 in Science Translational Medicine.

T cell-based therapies are among the most promising approaches to treat advanced cancer and are the subject of intense research, explains lead study author Brian Mog, M.D., Ph.D., an internal medicine resident at Brigham and Women’s Hospital in Boston. He was a medical and graduate student at the Johns Hopkins University School of Medicine when the research was conducted.

However, TCR and CAR (chimeric antigen receptor, usually using antibody as the detector), which are aimed at stimulating an immune response by activating T cells, each has limits. The combination of the two can overcome these limitations.

“We needed to make a new type of cell, because we were trying to target specific antigens called peptide-HLA (human leukocyte antigen) antigens, which are peptide fragments from mutant proteins inside the cancer cell that are displayed on the cell surface by peptide-holding proteins called HLAs,” Mog explains. Their specific target was a peptide containing the R175H mutation of p53 (the 175th amino acid of p53 is mutated from arginine to histidine), displayed on the HLA-A2 allele (gene variation). This is the most common mutation in the tumor suppressor protein p53, which is in turn the most commonly mutated gene in human cancers. 

However, these antigens are present at very low numbers (just one to 10) on a cancer cell, and the classic CAR format would not be able to react to such a small amount.  “Our goal was to combine some of the advantages of the CAR format with those of the natural T cell receptor on T cells, supplemented with additional signaling boosters, so that they could fight cancers more effectively,” Mog says.

The team went through multiple rounds of engineering to come up with the final design, testing their receptors in model cancer cell lines in test tubes and then in mouse models of cancer. The final Co-STAR T cells were able to continuously kill human cancer cells in test tubes.  When tested in mouse models of cancer, Co-STARs induced a robust, long-lasting proliferation of T cells that were able to induce profound remissions, and often cure, human cancer cells growing in mice. By contrast, more conventional T cells or CAR T cells were not able to eradicate the cancer cells in vitro and only brought about temporary tumor control in mice, with the cancers re-emerging days later. 

“Brian’s results demonstrated that Co-STAR T cells combine the advantages of many features of immune cells that normally fight infection in a way that allowed them to effectively kill cancer cells in mouse models,” says co-senior investigator Bert Vogelstein, M.D., Clayton Professor of Oncology, Howard Hughes Medical Institute investigator and co-director of the Ludwig Center. “Co-STARs address some, but certainly not all, challenges confronting T cell-based therapeutics but are certainly worthy of continued investigation.”

“I was, honestly, incredibly surprised that the Co-STARs worked so well in mice, given that I had generated so many different types of T cells over four years that could only slow the growth of cancers in mice” adds Mog. “Witnessing those cures was a very exciting moment.”

Study co-authors were Nikita Marcou, Sarah DiNapoli, Alexander Pearlman, Tushar Nichakawade, Michael Hwang, Jacqueline Douglass, Emily Han-Chung Hsiue, Stephanie Glavaris, Katharine Wright, Maximilian Konig, Suman Paul, Nicolas Wyhs, Jiaxin Ge, Michelle Miller, P. Aitana Azurmendi, Evangeline Watson, Drew Pardoll, Sandra Gabelli, Chetan Bettegowda, Nickolas Papadopoulos, Kenneth Kinzler and Shibin Zhou of Johns Hopkins.

The work was supported by the Virginia and D.K. Ludwig Fund for Cancer Research, the Lustgarten Foundation, the Commonwealth Fund, Bloomberg Philanthropies and the Bloomberg~Kimmel Institute for Cancer Immunotherapy, the National Institutes of Health (NH) Cancer Center Support Grant P30 CA006973, NIH grants (T32 GM136577, T32 AR048522, 1R21 AI176764, and K08CA270403), the National Institute of General Medical Sciences (grant T32GM148383), the National Cancer Institute (grants T32CA153952 and R37CA230400) and awards from the Leukemia & Lymphoma Society Translational Research Program, the American Society of Hematology, Swim Across America translational cancer research, the Jerome Greene Foundation, the Cupid Foundation, the Stephen and Renee Bisciotti Foundation, the Harrington Scholar-Innovator grant and the Rheumatology Research Foundation.

The Johns Hopkins University has filed patent applications related to technologies described in this paper on which Hsiue, Wright, Douglass, Mog, Hwang, Pearlman, Papadopoulos, Kinzler, Vogelstein, Gabelli, Pardoll and Zhou are listed as inventors. Vogelstein, Kinzler and Papadopoulos are founders of (and Kinzler and Papadopoulos are consultants to) Thrive Earlier Detection, an Exact Sciences company. Vogelstein, Kinzler, Papadopoulos and Zhou hold equity in Exact Sciences and are founders of or consultants to and own equity in Clasp Therapeutics, NeoPhore, and Personal Genome Diagnostics. Vogelstein, Kinzler and Papadopoulos are founders of or consultants to and own equity in Haystack Oncology and Cage Pharma. Papadopoulos is a consultant to Vidium. Vogelstein is a consultant to and holds equity in Catalio Capital Management. Zhou has a research agreement with BioMed Valley Discoveries. Bettegowda is a consultant to DePuy Synthes, Bionaut Labs, Haystack Oncology, Galectin Therapeutics, and Privo Technologies, and is a co-founder of OrisDX and Belay Diagnostics. Gabelli is a founder and holds equity in AMS LLC. Konig received consulting fees from Argenx, Atara Biotherapeutics, Revel Pharmaceuticals, Sana Biotechnology and Sanofi. Douglass previously consulted for Hemogenyx Pharmaceuticals. Paul is a consultant for Merck, owns equity in Gilead and received payment from IQVIA and Curio Science. Pardoll reports grant and patent royalties through Johns Hopkins from BMS, a grant from Compugen, stock from Trieza Therapeutics and Dracen Pharmaceuticals, and founder equity from Potenza. He is a consultant for Aduro Biotech, Amgen, AstraZeneca (MedImmune/Amplimmune), Bayer, DNAtrix, Dynavax Technologies, Ervaxx, FLX Bio, Rock Springs Capital, Janssen, Merck, Tizona and Immunomic Therapeutics. Pardoll is also on the scientific advisory boards of Five Prime Therapeutics, Camden Nexus II and WindMIL and the board of directors for Dracen Pharmaceuticals. Wright and Gabelli are current or former employees of Merck Sharp & Dohme and may own stock or stock options. The companies named above, as well as others, have licensed previously described technologies related to the work described in this paper from The Johns Hopkins University. Vogelstein, Kinzler and Papadopoulos are inventors of some of these technologies. Licenses for these technologies are or will be associated with equity or royalty payments to the inventors as well as to The Johns Hopkins University. Patent applications for the work described in this paper may be filed by The Johns Hopkins University. The terms of all of these arrangements are being managed by The Johns Hopkins University in accordance with its conflict-of-interest policies.

END

[Attachments] See images for this press release:
New Co-STAR receptor shows promise treating cancers in laboratory study New Co-STAR receptor shows promise treating cancers in laboratory study 2 New Co-STAR receptor shows promise treating cancers in laboratory study 3

ELSE PRESS RELEASES FROM THIS DATE:

Novel genome editing approach restores hearing in adult preclinical models with genetic deafness

2024-07-10
The study also looked at safety of the AAV-mediated genome editing approach and found it had a good safety profile that includes little off-target effect and no detectable long-term integration of the AAV vector in the genome. “Our research suggested minimal potential risk and supports the feasibility of future clinical applications in humans,” said Wenliang Zhu, PhD, and physician-scientist Wan Du, MD, PhD, members of Chen’s lab at Mass Eye and Ear and first authors on the paper. The study, led by Zheng-Yi Chen, DPhil, an associate scientist in the Eaton-Peabody Laboratories at Mass Eye and Ear (a member of the ...

Rice’s Omid Veiseh elected to the Controlled Release Society College of Fellows

Rice’s Omid Veiseh elected to the Controlled Release Society College of Fellows
2024-07-10
HOUSTON – (July 10, 2024) – The Controlled Release Society (CRS), the premier international, multidisciplinary society dedicated to the science and technology of drug delivery, has elected Rice University bioengineer Omid Veiseh to its College of Fellows. The recognition is a prestigious acknowledgement of “outstanding and sustained contributions in the field of delivery science and technology,” according to the organization website. “I am deeply honored to be elected to the CRS College ...

Bringing quantum tools to high school classrooms

Bringing quantum tools to high school classrooms
2024-07-10
More than 70 high school students and science teachers gathered at Young Middle School in Arlington this summer to learn about quantum information science (QIS). The annual workshop and camp are part of a national pilot program called Quantum for All led by Karen Jo Matsler, assistant professor in practice and master teacher in the UTeach program at The University of Texas at Arlington. “Just the word ‘quantum’ scares people, which is why many teachers and school administrators ...

Novel pre-treatment process enhances PFAs removal from drinking water

Novel pre-treatment process enhances PFAs removal from drinking water
2024-07-10
In a groundbreaking effort to tackle the pervasive issue of PFAS contamination in drinking water, a research team at New Jersey Institute of Technology has received funding from the Bureau of Reclamation's Desalination and Water Purification Research program. This highly competitive grant, awarded to only eight projects out of over eighty applicants, supports their innovative project titled "Enhanced Coagulation for the Removal of Per- and Polyfluoroalkyl Substances using Hydrophobic Ion Pairing Approach Project." Arjun Venkatesan, associate ...

NASA’s Hubble finds strong evidence for intermediate-mass black hole in Omega Centauri

NASA’s Hubble finds strong evidence for intermediate-mass black hole in Omega Centauri
2024-07-10
Most known black holes are either extremely massive, like the supermassive black holes that lie at the cores of large galaxies, or relatively lightweight, with a mass of under 100 times that of the Sun. Intermediate-mass black holes (IMBHs) are scarce, however, and are considered rare "missing links" in black hole evolution. Now, an international team of astronomers has used more than 500 images from NASA's Hubble Space Telescope — spanning two decades of observations — to search for evidence of an intermediate-mass black hole by following the motion of seven ...

The Society for Nutrition Education and Behavior (SNEB) issues its position on how to address emergency food and nutrition needs in disaster preparedness

2024-07-10
Philadelphia, July 10, 2024 – Despite escalating disaster frequency and severity, guidance for addressing emergency food and nutrition needs is limited. However, existing literature offers insights on how to effectively address emergency food and nutrition assistance. A recent position paper issued by the Society for Nutrition Education and Behavior (SNEB) in the Journal of Nutrition Education and Behavior, published by Elsevier, states that for effective recovery from and resilience to disasters, it is essential that impacted individuals and communities have access to safe, nutritious, and culturally and contextually appropriate foods and beverages, and receive emergency-related ...

Tackling the challenge of coca plant ID: wild vs cultivated for cocaine

2024-07-10
A new paper published today in Molecular Biology and Evolution reveals that it's not as straightforward as it might seem. Despite decades of data collection by the United Nations Office on Drugs and Crime (UNODC), which has been valuable to monitor changes in areas occupied by illegal coca plantations in South America, there is no reliable scientific method to distinguish between different types of coca plants. South American coca plants have been essential to Andean and Amazonian communities for at least 8,000 years. It is within these communities that they are thought to have evolved from wild to domesticated coca plants. Their ...

BESSY II shows how solid-state batteries degrade

BESSY II shows how solid-state batteries degrade
2024-07-10
Solid-state batteries have several advantages: they can store more energy and are safer than batteries with liquid electrolytes. However, they do not last as long and their capacity decreases with each charge cycle. But it doesn't have to stay that way: Researchers are already on the trail of the causes. In the journal ACS Energy Letters, a team from HZB and Justus-Liebig-Universität, Giessen, presents a new method for precisely monitoring electrochemical reactions during the operation of a solid-state battery using photoelectron spectroscopy at BESSY II. The results ...

Researchers show promising material for solar energy gets its curious boost from entropy

Researchers show promising material for solar energy gets its curious boost from entropy
2024-07-10
Solar energy is critical for a clean-energy future. Traditionally, solar energy is harvested using silicon – the same semiconductor material used in everyday electronic devices.  But silicon solar panels have drawbacks: for instance, they’re expensive and hard to mount on curved surfaces. Researchers have developed alternative materials for solar-energy harvesting to solve such shortcomings. Among the most promising of these are called “organic” semiconductors, carbon-based semiconductors that are Earth-abundant, cheaper and environmentally friendly. “They can potentially lower the production cost for solar panels because these ...

Faculty physicians to establish new community "health village" at Mondawmin Mall

Faculty physicians to establish new community health village at Mondawmin Mall
2024-07-10
University of Maryland Faculty Physicians has entered into an agreement to lease 17,000 square feet of space at The Village at Mondawmin, which would establish a new community "health village," University of Maryland School of Medicine (UMSOM) Dean Mark T. Gladwin, MD, and Faculty Practice President William F. Regine, MD, announced today. It is part of a larger effort to work in partnership with the West Baltimore community to develop and implement health care delivery based on neighborhood needs and to improve patient access to healthcare. The Faculty Practice group of ...

LAST 30 PRESS RELEASES:

Samuel Pepys’ fashion prints reveal his guilty pleasure: Fancy French clothes

New genetic test will eliminate a form of inherited blindness in dogs

Cancer risk: Most Australian welders exposed to high levels of dangerous fumes

Two-in-one mapping of temperature and flow around microscale convective flows

Texas A&M engineers explore intelligence augmentation to improve safety

ORNL economist honored at international hydropower conference

UCLA selected by Centers for Medicare & Medicaid Services to test Medicare dementia care model

Fish adjust reproduction in response to predators

DDX41 and its unique contribution to myeloid leukemogenesis

Digital games on vaping devices could lure more youth to nicotine addiction

Cracking the code of hydrogen embrittlement

Long-term results from Testicular Cancer treatment are positive, study shows

EPA awards UMass Amherst nearly $6.4 million to help shrink the steel industry’s carbon footprint

Valentina Greco takes on new position as President of the ISSCR

Komen supports UVA Engineering researchers targeting ‘triple negative' breast cancer

Panel issues first guidelines to prevent anal cancer in people with HIV

Estimating rainfall intensity using surveillance audio and deep-learning

Targeting factors for chemoprevention and cancer interception to tackle mesothelioma

New snake discovery rewrites history, points to North America’s role in snake evolution

Large and unequal life expectancy declines in India during COVID-19

A study of 156,000 UK residents found that urban residents score the lowest in social and economic satisfaction and well-being

Global study by Hawaiʻi Institute of Marine Biology demonstrates benefit of marine protected areas to recreational fisheries

Researchers clarify how soft materials fail under stress

Revolutionizing the abilities of adaptive radar with AI

Plastic waste can now be converted to electronic devices

Health equity scholar Darrell Hudson named Health Behavior and Health Education chair at the University of Michigan School of Public Health

Research will establish best ‘managed retreat’ practices for communities faced with climate change disaster

Marshall University awarded grant to further fentanyl addiction research

Wash U researchers shine light on amyloid architecture

New dawn for space storm alerts could help shield Earth's tech

[Press-News.org] New Co-STAR receptor shows promise treating cancers in laboratory study